DF/HCC Program Affiliation

Cancer Immunology
Lymphoma and Myeloma, Co-Leader
Translational Pharmacology and Early Therapeutic Trials

DF/HCC Associations

Member, Center Scientific Council
Principal Investigator, Myeloma SPORE

Research Abstract

Our laboratory efforts focus on translational research in multiple myeloma. We characterize factors in the marrow microenvironment which allow tumor cell homing, growth and resistance to apoptosis in the marrow millieu in order to devise therapies which interrupt these processes. We are delineating signaling cascades mediating growth, death, and resistance to apoptosis in myeloma cells in order to devise novel treatment strategies which interrupt growth, trigger apoptosis, and overcome drug resistance. Finally, our efforts are directed to delinate mechanisms for enhancing allogeneic and autologous immunity to myeloma cells in order to derive related novel vaccincation and adoptive immunotherapy treatments.

Publications

• Sukhdeo K, Mani M, Zhang Y, Dutta J, Yasui H, Rooney MD, Carrasco DE, Zheng M, He H, Tai YT, Mitsiades C, Anderson KC, Carrasco DR.Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma.Proc Natl Acad Sci U S A 2007 Ma
  17452641
• Carrasco DR, Sukhdeo K, Protopopova M, Sinha R, Enos M, Carrasco DE, Zheng M, Mani M, Henderson J, Pinkus GS, Munshi N, Horner J, Ivanova EV, Protopopov A, Anderson KC, Tonon G, DePinho RA.The differentiation and stress response factor XBP-1 drives multip
  17418411
• Podar K, Raab MS, Tonon G, Sattler M, Barilà D, Zhang J, Tai YT, Yasui H, Raje N, Depinho RA, Hideshima T, Chauhan D, Anderson KC.Up-Regulation of c-Jun Inhibits Proliferation and Induces Apoptosis via Caspase-Triggered c-Abl Cleavage in Human Multiple My
  17308109
• Alsayed Y, Ngo H, Runnels J, Leleu X, Singha UK, Pitsillides CM, Spencer JA, Kimlinger T, Ghobrial JM, Jia X, Lu G, Timm M, Kumar A, Côté D, Veilleux I, Hedin KE, Roodman GD, Witzig TE, Kung AL, Hideshima T, Anderson KC, Lin CP, Ghobrial IM.Mechanisms of
  17119115
• Shringarpure R, Catley L, Bhole D, Burger R, Podar K, Tai YT, Kessler B, Galardy P, Ploegh H, Tassone P, Hideshima T, Mitsiades C, Munshi NC, Chauhan D, Anderson KC.Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib.Br J Ha
  16846475
• Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M, Schlossman RL, Rajkumar SV, Desikan KR, Hideshima T, Munshi NC, Kelly-Colson K, Doss D, McKenney ML, Gorelik S, Warren D, Freeman A, Rich R, Wu A, Olesnyckyj M, Wride K, Dalton WS
  16840727
• Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B, Stewart JP, Zhan F, Khatry D, Protopopova M, Protopopov A, Sukhdeo K, Hanamura I, Stephens O, Barlogie B, Anderson KC, Chin L, Shaughnessy JD, Brennan C, Depinho RA.High-resolution genomic profiles
  16616336
• Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Kung AL, Davies FE, Morgan G, Akiyama M, Shringarpure R, Munshi NC, Richardson PG, Hideshima T, Chauhan D, Gu X, Bailey C, Joseph M, Libermann TA, Rosen NS, Anderson KC.Anti-myeloma activity of heat shoc
  16234364
• Chauhan D, Hideshima T, Pandey P, Treon S, Teoh G, Raje N, Rosen S, Krett N, Husson H, Avraham S, Kharbanda S, Anderson KC.RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells.Oncogene 1999 Nov 18;18(48):6733-40.
  10597281
• Chauhan D, Hideshima T, Treon S, Teoh G, Raje N, Yoshihimito S, Tai YT, Li W, Fan J, DeCaprio J, Anderson KC.Functional interaction between retinoblastoma protein and stress-activated protein kinase in multiple myeloma cells.Cancer Res 1999 Mar 15;59(6):1
  10096546
• Vallet S, Palumbo A, Raje N, Boccadoro M, Anderson KC.Thalidomide and lenalidomide: Mechanism-based potential drug combinations.Leuk Lymphoma 2008 Apr 23:1-8.
  18452080
• Chauhan D, Hideshima T, Anderson KC.Targeting proteasomes as therapy in multiple myeloma.Adv Exp Med Biol 2008;615:251-60.
  18437898
• San-Miguel J, Harousseau JL, Joshua D, Anderson KC.Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents.J Clin Oncol 2008 Apr 21.
  18427148
• Raje N, Woo SB, Hande K, Yap JT, Richardson PG, Vallet S, Treister N, Hideshima T, Sheehy N, Chhetri S, Connell B, Xie W, Tai YT, Szot-Barnes A, Tian M, Schlossman RL, Weller E, Munshi NC, Van Den Abbeele AD, Anderson KC.Clinical, radiographic, and bioche
  18413829
• Okawa Y, Hideshima T, Ikeda H, Raje N, Vallet S, Kiziltepe T, Yasui H, Enatsu S, Pozzi S, Breitkreutz I, Cirstea D, Santo L, Richardson P, Anderson KC.Fatty acid synthase is a novel therapeutic target in multiple myeloma.British Journal of Haematology 200
  18410446
• Ishitsuka K, Hideshima T, Neri P, Vallet S, Shiraishi N, Okawa Y, Shen Z, Raje N, Kiziltepe T, Ocio EM, Chauhan D, Tassone P, Munshi N, Campbell RM, Dios AD, Shih C, Starling JJ, Tamura K, Anderson KC.p38 mitogen-activated protein kinase inhibitor LY22288
  18397345
• Roccaro AM, Leleu X, Sacco A, Moreau AS, Hatjiharissi E, Jia X, Xu L, Ciccarelli B, Patterson CJ, Ngo HT, Russo D, Vacca A, Dammacco F, Anderson KC, Ghobrial IM, Treon SP.Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenstrom's
  18347188
• Richardson PG, Niesvizky R, Anderson KC, Blade J.Re: When you look matters: the effect of assessment schedule on progression-free survival.Journal of the National Cancer Institute 2008 Mar 5;100(5):373.
  18314478
• Richardson P, Mitsiades C, Colson K, Reilly E, McBride L, Chiao J, Sun L, Ricker J, Rizvi S, Oerth C, Atkins B, Fearen I, Anderson K, Siegel D.Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myel
  18297527
• Huston A, Leleu X, Jia X, Moreau AS, Ngo HT, Runnels J, Anderson J, Alsayed Y, Roccaro A, Vallet S, Hatjiharissi E, Tai YT, Sportelli P, Munshi N, Richardson P, Hideshima T, Roodman DG, Anderson KC, Ghobrial IM.Targeting Akt and heat shock protein 90 prod
  18245550
• Mukherjee S, Raje N, Schoonmaker JA, Liu JC, Hideshima T, Wein MN, Jones DC, Vallet S, Bouxsein ML, Pozzi S, Chhetri S, Seo YD, Aronson JP, Patel C, Fulciniti M, Purton LE, Glimcher LH, Lian JB, Stein G, Anderson KC, Scadden DT.Pharmacologic targeting of
  18219387
• Jinushi M, Vanneman M, Munshi NC, Tai YT, Prabhala RH, Ritz J, Neuberg D, Anderson KC, Carrasco DR, Dranoff G.MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma.Proc Natl Acad Sci U S A 2008
  18202175
• McGlynn KA, Gridley G, Mellemkjaer L, Brinton LA, Anderson KC, Caporaso NE, Landgren O, Olsen JH.Risks of cancer among a cohort of 23,935 men and women with osteoporosis.Int J Cancer 2008 Apr 15;122(8):1879-84.
  18074348
• Mitsiades CS, Hayden PJ, Anderson KC, Richardson PG.From the bench to the bedside: emerging new treatments in multiple myeloma.Best Pract Res Clin Haematol 2007 Dec;20(4):797-816.
  18070720
• Podar K, Richardson PG, Hideshima T, Chauhan D, Anderson KC.The malignant clone and the bone-marrow environment.Best Pract Res Clin Haematol 2007 Dec;20(4):597-612.
  18070708
• Chauhan D, Singh A, Brahmandam M, Podar K, Hideshima T, Richardson P, Munshi N, Palladino MA, Anderson KC.Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.Blood 2008 Feb 1;111(3):165
  18006697
• Hideshima T, Anderson KC.Preclinical studies of novel targeted therapies.Hematol Oncol Clin North Am 2007 Dec;21(6):1071-91, viii-ix.
  17996589
• Bae J, Mitsiades C, Tai YT, Bertheau R, Shammas M, Batchu RB, Li C, Catley L, Prabhala R, Anderson KC, Munshi NC.Phenotypic and functional effects of heat shock protein 90 inhibition on dendritic cell.J Immunol 2007 Jun 15;178(12):7730-7.
  17548610
• Munshi NC, Mitsiades CS, Richardson PG, Anderson KC.Does maintenance therapy with thalidomide benefit patients with multiple myeloma?.Nat Clin Pract Oncol 2007 May 29.
  17534287
• Tai YT, Fulciniti M, Hideshima T, Song W, Leiba M, Li XF, Rumizen M, Burger P, Morrison A, Podar K, Chauhan D, Tassone P, Richardson P, Munshi NC, Ghobrial I, Anderson KC.Targeting MEK induces myeloma cell cytotoxicity and inhibits osteoclastogenesis.Bloo
  17510321
• Hatjiharissi E, Xu L, Santos DD, Hunter ZR, Ciccarelli BT, Verselis S, Modica M, Cao Y, Manning RJ, Leleu X, Dimmock EA, Kortsaris A, Mitsiades C, Anderson KC, Fox EA, Treon SP.Increased natural killer cell expression of CD16, and augmented binding and AD
  17475906
• Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, San Miguel JF, Cavenagh JD, Anderson KC.Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.Bri
  17451408
• Hatjiharissi E, Ngo H, Leontovich AA, Leleu X, Timm M, Melhem M, George D, Lu G, Ghobrial J, Alsayed Y, Zeismer S, Cabanela M, Nehme A, Jia X, Moreau AS, Treon SP, Fonseca R, Gertz MA, Anderson KC, Witzig TE, Ghobrial IM.Proteomic analysis of waldenstrom
  17440091
• Podar K, Richardson PG, Chauhan D, Anderson KC.Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma.Expert Rev Anticancer Ther 2007 Apr;7(4):551-66.
  17428175
• Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, Macconnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K, Ziaugra L, Wong KK, Gabriel S, Beroukhim R, Peyton M, Barretina J, Dutt A, Emery
  17392811
• Kiziltepe T, Hideshima T, Ishitsuka K, Ocio EM, Raje N, Catley L, Li CQ, Trudel LJ, Yasui H, Vallet S, Kutok JL, Chauhan D, Mitsiades CS, Saavedra JE, Wogan GN, Keefer LK, Shami PJ, Anderson KC.JS-K, a GST-activated nitric oxide generator, induces DNA dou
  17384201
• Richardson PG, Hideshima T, Mitsiades C, Anderson KC.The emerging role of novel therapies for the treatment of relapsed myeloma.J Natl Compr Canc Netw 2007 Feb;5(2):149-62.
  17335684
• Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Comenzo RL, De Castro CM, Djulbegovic B, Farag S, Huff CA, Meredith R, Schriber J, Shrieve D, Singhal S, Smith MR, Stockerl-Goldstein K, Vose JM, Weber D, Yahalom J, Yunus F,.Multiple myeloma
  17335683
• Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K, Ziaugra L, Wong KK, Gabriel S, Beroukhim R, Peyton M, Barretina J, Dutt A, Emery C,
  17293865
• Yasui H, Hideshima T, Ikeda H, Ocio EM, Kiziltepe T, Vallet S, Okawa Y, Neri P, Sukhdeo K, Podar K, Chauhan D, Richardson PG, Raje N, Carrasco DR, Anderson KC.Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associa
  17268521
• Koreth J, Cutler CS, Djulbegovic B, Behl R, Schlossman RL, Munshi NC, Richardson PG, Anderson KC, Soiffer RJ, Alyea EP.High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review a
  17241924
• Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S, Koenig E, Fergus A, Huang Y, Richardson P, Trepicchio WL, Broyl A, Sonneveld P, Shaughnessy JD, Bergsagel PL, Schenkein D, Esseltine DL, Boral A, Anderson KC.Gene expression profiling and correl
  17185464
• Yasui H, Hideshima T, Ikeda H, Jin J, Ocio EM, Kiziltepe T, Okawa Y, Vallet S, Podar K, Ishitsuka K, Richardson PG, Pargellis C, Moss N, Raje N, Anderson KC.BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and
  17173546
• Podar K, Tonon G, Sattler M, Tai YT, Legouill S, Yasui H, Ishitsuka K, Kumar S, Kumar R, Pandite LN, Hideshima T, Chauhan D, Anderson KC.The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple
  17164332
• Francis LK, Alsayed Y, Leleu X, Jia X, Singha UK, Anderson J, Timm M, Ngo H, Lu G, Huston A, Ehrlich LA, Dimmock E, Lentzsch S, Hideshima T, Roodman GD, Anderson KC, Ghobrial IM.Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhib
  17121904
• Jagannath S, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Cowan JM, Anderson KC.Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials.Leukemia 2007 Jan;21(
  17096017
• Podar K, Raab MS, Zhang J, McMillin D, Breitkreutz I, Tai YT, Lin BK, Munshi N, Hideshima T, Chauhan D, Anderson KC.Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY3176
  17023575
• Koushik A, Hunter DJ, Spiegelman D, Anderson KE, Buring JE, Freudenheim JL, Goldbohm RA, Hankinson SE, Larsson SC, Leitzmann M, Marshall JR, McCullough ML, Miller AB, Rodriguez C, Rohan TE, Ross JA, Schatzkin A, Schouten LJ, Willett WC, Wolk A, Zhang SM,
  16823847
• Tai YT, Li XF, Breitkreutz I, Song W, Neri P, Catley L, Podar K, Hideshima T, Chauhan D, Raje N, Schlossman R, Richardson P, Munshi NC, Anderson KC.Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow
  16818641
• Jagannath S, Richardson PG, Barlogie B, Berenson JR, Singhal S, Irwin D, Srkalovic G, Schenkein DP, Esseltine DL, Anderson KC,.Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with
  16818280
• Shammas MA, Neri P, Koley H, Batchu RB, Bertheau RC, Munshi V, Prabhala R, Fulciniti M, Tai YT, Treon SP, Goyal RK, Anderson KC, Munshi NC.Specific killing of multiple myeloma cells by (-)- epigallocatechin-3-gallate extracted from green tea: biological a
  16809610
• Neri P, Yasui H, Hideshima T, Tassone P, Raje N, Laurence CP, Ishitsuka K, Blotta S, Kiziltepe T, Ocio EM, Fulciniti M, Kanekal S, Elliott GT, Munshi NC, Anderson KC.In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resi
  16803565
• Santos DD, Hatjiharissi E, Tournilhac O, Chemaly MZ, Leleu X, Xu L, Patterson C, Branagan AR, Manning RJ, Ho AW, Hunter ZR, Dimmock EA, Kutok JL, Churchill WH, Castells MC, Tai YT, Anderson KC, Treon SP.CD52 is expressed on human mast cells and is a poten
  16796779
• Tournilhac O, Santos DD, Xu L, Kutok J, Tai YT, Le Gouill S, Catley L, Hunter Z, Branagan AR, Boyce JA, Munshi N, Anderson KC, Treon SP.Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling.Ann On
  16788002
• Mitsiades CS, Mitsiades NS, Munshi NC, Richardson PG, Anderson KC.The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: Interplay of growth factors, their receptors and stromal interactions.Eur J Canc
  16765041
• Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA.Frequency, charac
  16754936
• Catley L, Weisberg E, Kiziltepe T, Tai YT, Hideshima T, Neri P, Tassone P, Atadja P, Chauhan D, Munshi NC, Anderson KC.Aggresome induction by proteasome inhibitor bortezomib and {alpha}-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH5
  16728695
• Mitsiades CS, Richardson PG, Anderson KC.The theraputic use of vitamin K compounds in multiple myeloma.Haematologica 2006 May;91(5):578b.
  16670056
• Navas TA, Nguyen AN, Hideshima T, Reddy M, Ma JY, Haghnazari E, Henson M, Stebbins EG, Kerr I, O'Young G, Kapoun AM, Chakravarty S, Mavunkel B, Perumattam J, Luedtke G, Dugar S, Medicherla S, Protter AA, Schreiner GF, Anderson KC, Higgins LS.Inhibition of
  16617327
• Richardson PG, Schlossman R, Hideshima T, Anderson KC.New treatments for multiple myeloma.Oncology (Huntingt) 2005 Dec;19(14):1781-92; discussion 1792,.
  16506632
• Genkinger JM, Hunter DJ, Spiegelman D, Anderson KE, Arslan A, Beeson WL, Buring JE, Fraser GE, Freudenheim JL, Goldbohm RA, Hankinson SE, Jacobs DR Jr, Koushik A, Lacey JV Jr, Larsson SC, Leitzmann M, McCullough ML, Miller AB, Rodriguez C, Rohan TE, Schou
  16492930
• Genkinger JM, Hunter DJ, Spiegelman D, Anderson KE, Buring JE, Freudenheim JL, Goldbohm RA, Harnack L, Hankinson SE, Larsson SC, Leitzmann M, McCullough ML, Marshall J, Miller AB, Rodriguez C, Rohan TE, Schatzkin A, Schouten LJ, Wolk A, Zhang SM, Smith-Wa
  16495916
• Genkinger JM, Hunter DJ, Spiegelman D, Anderson KE, Beeson WL, Buring JE, Colditz GA, Fraser GE, Freudenheim JL, Goldbohm RA, Hankinson SE, Koenig KL, Larsson SC, Leitzmann M, McCullough ML, Miller AB, Rodriguez C, Rohan TE, Ross JA, Schatzkin A, Schouten
  16489535
• Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin DH, Rajkumar SV, Srkalovic G, Alsina M, Anderson KC.Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.Ca
  16470606
• Podar K, Anderson KC.Caveolin-1 as a potential new therapeutic target in multiple myeloma.Cancer Lett 2006 Feb 20;233(1):10-5.
  16473666
• Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, McCoy J, Dakhil SR, Lanier KS, Chapman RA, Cromer JN, Salmon SE, Durie B, Crowley JC.Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of p
  16432076
• Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C, Podar K, Munshi NC, Chauhan D, Richardson PG, Anderson KC.Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple
  16418332
• Richardson PG, Mitsiades C, Hideshima T, Anderson KC.Bortezomib: proteasome inhibition as an effective anticancer therapy.Annu Rev Med 2006;57:33-47.
  16409135
• Roccaro AM, Hideshima T, Raje N, Kumar S, Ishitsuka K, Yasui H, Shiraishi N, Ribatti D, Nico B, Vacca A, Dammacco F, Richardson PG, Anderson KC.Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.C
  16397231
• Hideshima T, Bradner JE, Chauhan D, Anderson KC.Intracellular protein degradation and its therapeutic implications.Clin Cancer Res 2005 Dec 15;11(24 Pt 1):8530-3.
  16361533
• Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, Mitsiades C, Mitsiades N, Yasui H, Letai A, Ovaa H, Berkers C, Nicholson B, Chao TH, Neuteboom ST, Richardson P, Palladino MA, Anderson KC.A novel orally active proteasome inhibitor induces apop
  16286248
• Kumar S, Anderson KC.Drug insight: thalidomide as a treatment for multiple myeloma.Nat Clin Pract Oncol 2005 May;2(5):262-70.
  16264962
• Koushik A, Hunter DJ, Spiegelman D, Anderson KE, Arslan AA, Beeson WL, van den Brandt PA, Buring JE, Cerhan JR, Colditz GA, Fraser GE, Freudenheim JL, Genkinger JM, Goldbohm RA, Hankinson SE, Koenig KL, Larsson SC, Leitzmann M, McCullough ML, Miller AB, P
  16172226
• Anderson KC, Pazdur R, Farrell AT.Development of effective new treatments for multiple myeloma.J Clin Oncol 2005 Oct 1;23(28):7207-11.
  16145064
• Chen J, Lee BH, Williams IR, Kutok JL, Mitsiades CS, Duclos N, Cohen S, Adelsperger J, Okabe R, Coburn A, Moore S, Huntly BJ, Fabbro D, Anderson KC, Griffin JD, Gilliland DG.FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoi
  16091734
• Richardson PG, Mitsiades CS, Hideshima T, Anderson KC.Novel biological therapies for the treatment of multiple myeloma.Best Pract Res Clin Haematol 2005;18(4):619-34.
  16026741
• Catley L, Tai YT, Chauhan D, Anderson KC.Perspectives for combination therapy to overcome drug-resistant multiple myeloma.Drug Resist Updat 2005 Aug;8(4):205-18.
  16019253
• Mitsiades CS, Mitsiades N, Hideshima T, Richardson PG, Anderson KC.Proteasome inhibition as a therapeutic strategy for hematologic malignancies.Expert Rev Anticancer Ther 2005 Jun;5(3):465-76.
  16001954
• Tai YT, Li X, Tong X, Santos D, Otsuki T, Catley L, Tournilhac O, Podar K, Hideshima T, Schlossman R, Richardson P, Munshi NC, Luqman M, Anderson KC.Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma
  15994968
• Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Blade J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson K
  15958804
• Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL, Anderson KC.Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.Proc Natl Acad Sci U S A 2005 Jun 14;102(24):8567
  15937109
• Vasir B, Borges V, Wu Z, Grosman D, Rosenblatt J, Irie M, Anderson K, Kufe D, Avigan D.Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation.Br J Haematol 2005 Jun;129(5):687-700.
  15916692
• Ishitsuka K, Hideshima T, Hamasaki M, Raje N, Kumar S, Hideshima H, Shiraishi N, Yasui H, Roccaro AM, Richardson P, Podar K, Le Gouill S, Chauhan D, Tamura K, Arbiser J, Anderson KC.Honokiol overcomes conventional drug resistance in human multiple myeloma
  15870175
• Tassone P, Neri P, Carrasco DR, Burger R, Goldmacher VS, Fram R, Munshi V, Catley L, Jacob GS, Venuta S, Anderson KC, Munshi NC.A clinically relevant SCID-hu in vivo model of human multiple myeloma.Blood 2005 Apr 7.
  15817674
• Anderson KC.Clinical update: novel targets in multiple myeloma.Semin Oncol 2004 Dec;31(6 Suppl 16):27-32; discussion 33.
  15799242
• Bellucci R, Alyea EP, Chiaretti S, Wu CJ, Zorn E, Weller E, Wu B, Canning C, Schlossman R, Munshi NC, Anderson KC, Ritz J.Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane re
  15692072
• Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby E, Frankel SR, Touroutoglou N, Turnbull B, Anderson KC, Maloney DG, Fox EA.Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in W
  15659493
• Rajkumar SV, Richardson PG, Hideshima T, Anderson KC.Proteasome inhibition as a novel therapeutic target in human cancer.J Clin Oncol 2005 Jan 20;23(3):630-9.
  15659509
• Richardson PG, Mitsiades C, Hideshima T, Anderson KC.Proteasome inhibition in the treatment of cancer.Cell Cycle 2005 Feb;4(2):290-6.
  15655370
• Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N, Kumar S, Chauhan D, Treon SP, Richardson P, Anderson KC.Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.Br J Haematol 2005 Jan;128(2):192-
  15638853
• Treon SP, Emmanouilides C, Kimby E, Kelliher A, Preffer F, Branagan AR, Anderson KC, Frankel SR,.Extended rituximab therapy in Waldenström's macroglobulinemia.Ann Oncol 2005 Jan;16(1):132-8.
  15598950
• Podar K, Anderson KC.The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications.Blood 2005 Feb 15;105(4):1383-95.
  15471951
• Lin B, Catley L, LeBlanc R, Mitsiades C, Burger R, Tai YT, Podar K, Wartmann M, Chauhan D, Griffin JD, Anderson KC.Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo.Blood 2005 Jan 1;105(1):350-7.
  15367426
• Craiu A, Saito Y, Limon A, Eppich HM, Olson DP, Rodrigues N, Adams GB, Dombkowski D, Richardson P, Schlossman R, Choi PS, Grogins J, O'Connor PG, Cohen K, Attar EC, Freshman J, Rich R, Mangano JA, Gribben JG, Anderson KC, Scadden DT.Flowing cells through
  15292069
• Le Gouill S, Podar K, Amiot M, Hideshima T, Chauhan D, Itshitsuka K, Kumar S, Raje N, Richardson PG, Harousseau JL, Anderson KC.VEGF induces MCL-1 upregulation and protects multiple myeloma cells against apoptosis.Blood 2004 Jun 24.
  15217829
• Tai YT, Catley LP, Mitsiades CS, Burger R, Podar K, Shringpaure R, Hideshima T, Chauhan D, Hamasaki M, Ishitsuka K, Richardson P, Treon SP, Munshi NC, Anderson KC.Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human mu
  15087402
• Raje N, Hideshima T, Davies FE, Chauhan D, Treon SP, Young G, Tai YT, Avigan D, Gong J, Schlossman RL, Richardson P, Kufe DW, Anderson KC.Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma.Br J Haematol 2004 May;125(3):343-5
  15086415
• Chauhan D, Li G, Podar K, Hideshima T, Shringarpure R, Catley L, Mitsiades C, Munshi N, Tai YT, Suh N, Gribble GW, Honda T, Schlossman R, Richardson P, Sporn MB, Anderson KC.The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synerg
  15070698
• Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, Hideshima T, Chauhan D, Joseph M, Libermann TA, García-Echeverría C, Pearson MA, Hofmann F, Anderson KC, Kung AL.Inhibition of the insulin-like growth factor receptor-1 tyrosin
  15050914
• Chauhan D, Li G, Auclair D, Hideshima T, Podar K, Mitsiades N, Mitsiades C, Chen LB, Munshi N, Saxena S, Anderson KC.2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shoc
  15004512
• Hideshima T, Richardson PG, Anderson KC.Targeting proteasome inhibition in hematologic malignancies.Rev Clin Exp Hematol 2003 Jun;7(2):191-204.
  14763162
• Shammas MA, Reis RJ, Li C, Koley H, Hurley LH, Anderson KC, Munshi NC.Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma.Clin Cancer Res 2004 Jan 15;10(2):770-6.
  14760100
• Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, Akiyama M, Chauhan D, Munshi N, Gu X, Bailey C, Joseph M, Libermann TA, Richon VM, Marks PA, Anderson KC.Transcriptional signature of histone deacetylase inhibition in multip
  14695887
• Anderson KC.Stem cell transplantation for myeloma.Curr Hematol Rep 2004 Jan;3(1):65-6.
  14695853
• Hideshima T, Chauhan D, Hayashi T, Podar K, Akiyama M, Mitsiades C, MItsiades N, Gong B, Bonham L, de Vries P, Munshi N, Richardson PG, Singer JW, Anderson KC.Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of ag
  14679006
• Alyea E, Weller E, Schlossman R, Canning C, Mauch P, Ng A, Fisher D, Gribben J, Freeman A, Parikh B, Richardson P, Soiffer R, Ritz J, Anderson KC.Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact
  14647268
• Podar K, Catley LP, Tai YT, Shringarpure R, Carvalho P, Hayashi T, Burger R, Schlossman RL, Richardson PG, Pandite LN, Kumar R, Hideshima T, Chauhan D, Anderson KC.GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple
  14644994
• Burger R, Bakker F, Guenther A, Baum W, Schmidt-Arras D, Hideshima T, Tai YT, Shringarpure R, Catley L, Senaldi G, Gramatzki M, Anderson KC.Functional significance of novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) for human
  14632778
• Hideshima T, Chauhan D, Hayashi T, Akiyama M, Mitsiades N, Mitsiades C, Podar K, Munshi NC, Richardson PG, Anderson KC.Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myelom
  14627979
• Mitsiades CS, Mitsiades NS, Bronson RT, Chauhan D, Munshi N, Treon SP, Maxwell CA, Pilarski L, Hideshima T, Hoffman RM, Anderson KC.Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical impli
  14583463
• Richardson PG, Hideshima T, Anderson KC.Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers.Cancer Control 2003 Sep-Oct;10(5):361-9.
  14581890
• Bellucci R, Wu CJ, Chiaretti S, Weller E, Davies FE, Alyea EP, Dranoff G, Anderson KC, Munshi NC, Ritz J.Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens.Blood 2004 Jan 1
  14563636
• Akiyama M, Hideshima T, Shammas MA, Hayashi T, Hamasaki M, Tai YT, Richardson P, Gryaznov S, Munshi NC, Anderson KC.Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells.Cancer Res 2
  14559802
• Chauhan D, Li G, Shringarpure R, Podar K, Ohtake Y, Hideshima T, Anderson KC.Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells.Cancer Res 2003 Oct 1;63(19):6174-7.
  14559800
• Shammas MA, Shmookler Reis RJ, Akiyama M, Koley H, Chauhan D, Hideshima T, Goyal RK, Hurley LH, Anderson KC, Munshi NC.Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma.Mol Cancer Ther 2003 Sep;2(9):825-33.
  14555701
• Tai YT, Podar K, Catley L, Tseng YH, Akiyama M, Shringarpure R, Burger R, Hideshima T, Chauhan D, Mitsiades N, Richardson P, Munshi NC, Kahn CR, Mitsiades C, Anderson KC.Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma
  14522909
• LeBlanc R, Hideshima T, Catley LP, Shringarpure R, Burger R, Mitsiades N, Mitsiades C, Cheema P, Chauhan D, Richardson PG, Anderson KC, Munshi NC.Immunomodulatory drug costimulates T cells via the B7-CD28 pathway.Blood 2004 Mar 1;103(5):1787-90.
  14512311
• Chauhan D, Li G, Sattler M, Podar K, Mitsiades C, Mitsiades N, Munshi N, Hideshima T, Anderson KC.Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells.Oncogene 2003 Sep 18;22(40):6296-300.
  13679868
• Davies FE, Dring AM, Li C, Rawstron AC, Shammas MA, O'Connor SM, Fenton JA, Hideshima T, Chauhan D, Tai IT, Robinson E, Auclair D, Rees K, Gonzalez D, Ashcroft AJ, Dasgupta R, Mitsiades C, Mitsiades N, Chen LB, Wong WH, Munshi NC, Morgan GJ, Anderson KC.I
  12947006
• Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH.Proteasome inhibitors disrupt the unfolded protein response in myeloma cells.Proc Natl Acad Sci U S A 2003 Aug 19;100(17):9946-51.
  12902539
• Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC.A phase
  12826635
• Catley L, Weisberg E, Tai YT, Atadja P, Remiszewski S, Hideshima T, Mitsiades N, Shringarpure R, LeBlanc R, Chauhan D, Munshi NC, Schlossman R, Richardson P, Griffin J, Anderson KC.NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significan
  12816865
• Maecker B, Anderson KS, von Bergwelt-Baildon MS, Weller E, Vonderheide RH, Richardson PG, Schlossman RL, Menezes IA, Xia Z, Munshi NC, Anderson KC, Nadler LM, Schultze JL.Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma.Br J H
  12786794
• Hayashi T, Treon SP, Hideshima T, Tai YT, Akiyama M, Richardson P, Chauhan D, Grewal IS, Anderson KC.Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells.Br J
  12752100
• Orsini E, Bellucci R, Alyea EP, Schlossman R, Canning C, McLaughlin S, Ghia P, Anderson KC, Ritz J.Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion.Cancer Res 2003 May 15;63(10):2561-8.
  12750280
• Akiyama M, Hideshima T, Munshi NC, Anderson KC.Telomerase inhibitors as anticancer therapy.Curr Med Chem Anti-Canc Agents 2002 Sep;2(5):567-75.
  12678724
• Anderson KC.Moving disease biology from the lab to the clinic.Cancer 2003 Feb 1;97(3 Suppl):796-801.
  12548578
• Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G, Schlossman R, Chauhan D, Munshi NC, Hideshima T, Richon VM, Marks PA, Anderson KC.Molecular sequelae of histone deacetylase inhibition in human malignant B cells.Blood 2003 May
  12531799
• Lentzsch S, LeBlanc R, Podar K, Davies F, Lin B, Hideshima T, Catley L, Stirling DI, Anderson KC.Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo.Leukemia 2003 Jan;17(1):41-4.
  12529658
• Anderson KC.Moving disease biology from the laboratory to the clinic.Semin Oncol 2002 Dec;29(6 Suppl 17):17-20.
  12520480
• Akiyama M, Hideshima T, Hayashi T, Tai YT, Mitsiades CS, Mitsiades N, Chauhan D, Richardson P, Munshi NC, Anderson KC.Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein.
  12517770
• Hayashi T, Hideshima T, Akiyama M, Richardson P, Schlossman RL, Chauhan D, Munshi NC, Waxman S, Anderson KC.Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment.Mol Cancer Ther 2002 Aug;1(10):851-60.
  12492118
• Podar K, Tai YT, Cole CE, Hideshima T, Sattler M, Hamblin A, Mitsiades N, Schlossman RL, Davies FE, Morgan GJ, Munshi NC, Chauhan D, Anderson KC.Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated surviva
  12482878
• Chauhan D, Li G, Auclair D, Hideshima T, Richardson P, Podar K, Mitsiades N, Mitsiades C, Li C, Kim RS, Munshi N, Chen LB, Wong W, Anderson KC.Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide a
  12480690
• Hideshima T, Chauhan D, Hayashi T, Podar K, Akiyama M, Gupta D, Richardson P, Munshi N, Anderson KC.The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma.Mol Cancer Ther 2002 May;1(7):539-44.
  12479272
• Soiffer RJ, Alyea EP, Hochberg E, Wu C, Canning C, Parikh B, Zahrieh D, Webb I, Antin J, Ritz J.Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion.Biol Blood Marrow Transplant
  12463482
• Hideshima T, Anderson KC.Molecular mechanisms of novel therapeutic approaches for multiple myeloma.Nat Rev Cancer 2002 Dec;2(12):927-37.
  12459731
• Tai YT, Podar K, Mitsiades N, Lin B, Mitsiades C, Gupta D, Akiyama M, Catley L, Hideshima T, Munshi NC, Treon SP, Anderson KC.CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling.Blood 2003 Apr 1;10
  12433678
• Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Schlossman R, Munshi NC, Hideshima T, Anderson KC.The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cel
  12424198
• Hideshima T, Akiyama M, Hayashi T, Richardson P, Schlossman R, Chauhan D, Anderson KC.Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu.Blood 2003 Jan 15;101(2):703-5.
  12393542
• Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P, Schlossman R, Podar K, Munshi NC, Mitsiades N, Anderson KC.Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.Blood 2003 Feb 15;101(4):1530-4.
  12393500
• Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP, Munshi NC, Richardson PG, Hideshima T, Anderson KC.Molecular sequelae of proteasome inhibition in human multiple myeloma cells.Proc Natl Acad
  12391322
• Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, LeBlanc R, Catley LP, Doss D, Kelly K, McKenney M, Mechlowicz J, Freeman A, Deocampo R, Rich R, Ryoo JJ, Chauhan D, Balinski K, Zeldis J, Anderson KC.Immunomodulatory drug CC-5013
  12384400
• LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, Neuberg D, Goloubeva O, Pien CS, Adams J, Gupta D, Richardson PG, Munshi NC, Anderson KC.Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival
  12208752
• Lin B, Podar K, Gupta D, Tai YT, Li S, Weller E, Hideshima T, Lentzsch S, Davies F, Li C, Weisberg E, Schlossman RL, Richardson PG, Griffin JD, Wood J, Munshi NC, Anderson KC.The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787
  12208756
• Chauhan D, Catley L, Hideshima T, Li G, Leblanc R, Gupta D, Sattler M, Richardson P, Schlossman RL, Podar K, Weller E, Munshi N, Anderson KC.2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells.Blood 2002 Sep 15;100(6):2187-94.
  12200384
• Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KC.Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human m
  12173037
• Gupta D, Podar K, Tai YT, Lin B, Hideshima T, Akiyama M, LeBlanc R, Catley L, Mitsiades N, Mitsiades C, Chauhan D, Munshi NC, Anderson KC.beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells.Exp Hematol 2002 Jul
  12135668
• Akiyama M, Hideshima T, Hayashi T, Tai YT, Mitsiades CS, Mitsiades N, Chauhan D, Richardson P, Munshi NC, Anderson KC.Cytokines modulate telomerase activity in a human multiple myeloma cell line.Cancer Res 2002 Jul 1;62(13):3876-82.
  12097303
• Anderson RD, White HD, Ohman EM, Wagner GS, Krucoff MW, Armstrong PW, Weaver WD, Gibler WB, Stebbins AL, Califf RM, Topol EJ.Predicting outcome after thrombolysis in acute myocardial infarction according to ST-segment resolution at 90 minutes: a substudy
  12094192
• Brander C, Raje N, O'Connor PG, Davies F, Davis J, Chauhan D, Hideshima T, Martin J, Osmond D, Kedes DH, Walker BD, Scadden DT, Anderson KC.Absence of biologically important Kaposi sarcoma-associated herpesvirus gene products and virus-specific cellular i
  12091368
• Bellucci R, Alyea EP, Weller E, Chillemi A, Hochberg E, Wu CJ, Canning C, Schlossman R, Soiffer RJ, Anderson KC, Ritz J.Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma.Blood 2002 J
  12036895
• Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi NC, Treon SP, Anderson KC.Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.Blood 2002 Jun 15;9
  12036884
• Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi N, Treon SP, Anderson KC.Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications.Blood 2002 Jun 1;99(11):4079-86.
  12010810
• Alyea E, Neuberg D, Mauch P, Marcus K, Freedman A, Webb I, Anderson K, Schlossman R, Fisher D, Gribben J, Ritz J, Soiffer R.Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation.Biol B
  11939603
• Gong J, Koido S, Chen D, Tanaka Y, Huang L, Avigan D, Anderson K, Ohno T, Kufe D.Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12.Blood 2002 Apr 1;99(7):2512-7.
  11895787
• Tai YT, Podar K, Kraeft SK, Wang F, Young G, Lin B, Gupta D, Chen LB, Anderson KC.Translocation of Ku86/Ku70 to the multiple myeloma cell membrane: functional implications.Exp Hematol 2002 Mar;30(3):212-20.
  11882358
• Mitsiades N, Mitsiades CS, Poulaki V, Anderson KC, Treon SP.Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells.Blood 2002 Mar 15;99(6):2162-71.
  11877293
• Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, Adams J, Anderson KC.NF-kappa B as a therapeutic target in multiple myeloma.J Biol Chem 2002 May 10;277(19):16639-47.
  11872748
• Akiyama M, Yamada O, Kanda N, Akita S, Kawano T, Ohno T, Mizoguchi H, Eto Y, Anderson KC, Yamada H.Telomerase overexpression in K562 leukemia cells protects against apoptosis by serum deprivation and double-stranded DNA break inducing agents, but not agai
  11867204
• Chauhan D, Auclair D, Robinson EK, Hideshima T, Li G, Podar K, Gupta D, Richardson P, Schlossman RL, Krett N, Chen LB, Munshi NC, Anderson KC.Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays.Oncogen
  11857078
• Mitsiades N, Poulaki V, Mitsiades CS, Anderson KC.Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug.Expert Opin Investig Drugs 2001 Jun;10(6):1075-84.
  11772236
• Mitsiades N, Mitsiades CS, Poulaki V, Anderson KC, Treon SP.Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias.Expert Opin Investig Drugs 2001 Aug;10(8):1521-30.
  11772267
• Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, Lin B, Lentzsch S, Davies FE, Chauhan D, Schlossman RL, Richardson P, Ralph P, Wu L, Payvandi F, Muller G, Stirling DI, Anderson KC.Adherence of multiple myeloma cells to bone marrow stromal cells
  11753617
• Podar K, Tai YT, Lin BK, Narsimhan RP, Sattler M, Kijima T, Salgia R, Gupta D, Chauhan D, Anderson KC.Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-depe
  11751905
• Hideshima T, Chauhan D, Podar K, Schlossman RL, Richardson P, Anderson KC.Novel therapies targeting the myeloma cell and its bone marrow microenvironment.Semin Oncol 2001 Dec;28(6):607-12.
  11740818
• D'Amato RJ, Lentzsch S, Anderson KC, Rogers MS.Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma.Semin Oncol 2001 Dec;28(6):597-601.
  11740816
• Hideshima T, Nakamura N, Chauhan D, Anderson KC.Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma.Oncogene 2001 Sep 20;20(42):5991-6000.
  11593406
• Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R, Hideshima T, Anderson KC.TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.Blood 2001 Aug 1;98(3):795-804.
  11468181
• Treon SP, Agus TB, Link B, Rodrigues G, Molina A, Lacy MQ, Fisher DC, Emmanouilides C, Richards AI, Clark B, Lucas MS, Schlossman R, Schenkein D, Lin B, Kimby E, Anderson KC, Byrd JC.CD20-directed antibody-mediated immunotherapy induces responses and faci
  11394506
• Schultze JL, Anderson KC, Gilleece MH, Gribben JG, Nadler LM.A pilot study of combined immunotherapy with autologous adoptive tumour-specific T-cell transfer, vaccination with CD40-activated malignant B cells and interleukin 2.Br J Haematol 2001 May;113(2
  11380416
• Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC.The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.Cancer Res 2001 Apr 1;61(7):3071-6.
  11306489
• Soiffer RJ, Weller E, Alyea EP, Mauch P, Webb IL, Fisher DC, Freedman AS, Schlossman RL, Gribben J, Lee S, Anderson KC, Marcus K, Stone RM, Antin JH, Ritz J.CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in pa
  11181681
• Tai YT, Teoh G, Lin B, Davies FE, Chauhan D, Treon SP, Raje N, Hideshima T, Shima Y, Podar K, Anderson KC.Ku86 variant expression and function in multiple myeloma cells is associated with increased sensitivity to DNA damage.J Immunol 2000 Dec 1;165(11):63
  11086072
• Treon SP, Maimonis P, Bua D, Young G, Raje N, Mollick J, Chauhan D, Tai YT, Hideshima T, Shima Y, Hilgers J, von Mensdorff-Pouilly S, Belch AR, Pilarski LM, Anderson KC.Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with
  11049996
• Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT, Treon SP, Lin B, Schlossman RL, Richardson P, Muller G, Stirling DI, Anderson KC.Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.Blood
  11049970
• Orsini E, Alyea EP, Chillemi A, Schlossman R, McLaughlin S, Canning C, Soiffer RJ, Anderson KC, Ritz J.Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma.Biol Blood
  10917573
• Chauhan D, Pandey P, Hideshima T, Treon S, Raje N, Davies FE, Shima Y, Tai YT, Rosen S, Avraham S, Kharbanda S, Anderson KC.SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells.J Biol Chem
  10880513
• Ladetto M, Donovan JW, Harig S, Trojan A, Poor C, Schlossnan R, Anderson KC, Gribben JG.Real-Time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma.Biol Blood Marrow Tran
  10871149
• Hideshima T, Chauhan D, Teoh G, Raje N, Treon SP, Tai YT, Shima Y, Anderson KC.Characterization of signaling cascades triggered by human interleukin-6 versus Kaposi's sarcoma-associated herpes virus-encoded viral interleukin 6.Clin Cancer Res 2000 Mar;6(3
  10741750
• Orsini E, Alyea EP, Schlossman R, Canning C, Soiffer RJ, Chillemi A, Neuberg D, Anderson KC, Ritz J.Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma af
  10734296
• Freedman AS, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Fisher DC, Schlossman R, Alyea EP, Takvorian T, Jallow H, Kuhlman C, Ritz J, Nadler LM, Gribben JG.Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular
  10552941
• Treon SP, Shima Y, Preffer FI, Doss DS, Ellman L, Schlossman RL, Grossbard ML, Belch AR, Pilarski LM, Anderson KC.Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy.Semin Oncol 1999 Oct;26(5 Suppl 14):97-106.
  10561024
• Friedberg JW, Neuberg D, Gribben JG, Mauch P, Anderson KC, Soiffer RJ, Takvorian T, Fisher DC, Schlossman R, Jallow H, Kuhlman C, Ritz J, Freedman AS.Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies.Bi
  10465106
• Chauhan D, Bharti A, Raje N, Gustafson E, Pinkus GS, Pinkus JL, Teoh G, Hideshima T, Treon SP, Fingeroth JD, Anderson KC.Detection of Kaposi's sarcoma herpesvirus DNA sequences in multiple myeloma bone marrow stromal cells.Blood 1999 Mar 1;93(5):1482-6.
  10029574
• Raje N, Gong J, Chauhan D, Teoh G, Avigan D, Wu Z, Chen D, Treon SP, Webb IJ, Kufe DW, Anderson KC.Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kap
  10029575
• Treon SP, Mollick JA, Urashima M, Teoh G, Chauhan D, Ogata A, Raje N, Hilgers JH, Nadler L, Belch AR, Pilarski LM, Anderson KC.Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone.Blood 1999 Feb 15;93(4):1287-98.
  9949172
• Teoh G, Chen L, Urashima M, Tai YT, Celi LA, Chen D, Chauhan D, Ogata A, Finberg RW, Webb IJ, Kufe DW, Anderson KC.Adenovirus vector-based purging of multiple myeloma cells.Blood 1998 Dec 15;92(12):4591-601.
  9845525
• Webb IJ, Beach M, Daley JF, Schott DM, Anderson KC.Sequential CD34+ and CD4+ cell selection from leukapheresis components.J Hematother 1998 Apr;7(2):169-74.
  9597574
• Teoh G, Urashima M, Ogata A, Chauhan D, DeCaprio JA, Treon SP, Schlossman RL, Anderson KC.MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells.Blood 1997 Sep 1;90(5):1982-92.
  9292533
• Urashima M, Chen BP, Chen S, Pinkus GS, Bronson RT, Dedera DA, Hoshi Y, Teoh G, Ogata A, Treon SP, Chauhan D, Anderson KC.The development of a model for the homing of multiple myeloma cells to human bone marrow.Blood 1997 Jul 15;90(2):754-65.
  9226176
• Chauhan D, Kharbanda S, Ogata A, Urashima M, Teoh G, Robertson M, Kufe DW, Anderson KC.Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells.Blood 1997 Jan 1;89(1):227-34.
  8978296
• Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann TA, Anderson KC.Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B.Blood 1996 Feb 1;87(3):1104-12.
  8562936
• Chauhan D, Kharbanda SM, Ogata A, Urashima M, Frank D, Malik N, Kufe DW, Anderson KC.Oncostatin M induces association of Grb2 with Janus kinase JAK2 in multiple myeloma cells.J Exp Med 1995 Dec 1;182(6):1801-6.
  7500025
• Urashima M, Chauhan D, Uchiyama H, Freeman GJ, Anderson KC.CD40 ligand triggered interleukin-6 secretion in multiple myeloma.Blood 1995 Apr 1;85(7):1903-12.
  7535594
• Anderson KC, Andersen J, Soiffer R, Freedman AS, Rabinowe SN, Robertson MJ, Spector N, Blake K, Murray C, Freeman A.Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma.Blood 1993 Oct 15;82(8):2568-76.
  8400304